In Brief
The BCL-2 family member BOK offers a path to mitochondrial outer membrane permeabilization and apoptosis that can be executed in the absence of BAX and BAK and that is controlled at the level of protein stability by ER-associated degradation.
INTRODUCTION
The BCL-2 family proteins (hereafter BCL-2 proteins) are primary regulators of mitochondrial outer membrane permeabilization (MOMP), an essential event in mitochondrial apoptosis. MOMP results in the release of mitochondrial proteins such as cytochrome c, Smac, and Omi that promote caspase activation and apoptosis (Green and Llambi, 2015) . BAX and BAK are BCL-2 family effectors of MOMP. In their absence, cells are resistant to various apoptotic stimuli (Lindsten et al., 2000; Wei et al., 2001 ). Therefore, BAX and BAK are thought to be absolutely required for MOMP and the mitochondrial pathway of apoptosis. BAX and BAK activities are regulated though their interaction with BCL-2 family members. BH3-only proteins directly promote BAX and BAK activation, whereas antiapoptotic BCL-2 proteins antagonize proapoptotic proteins to prevent apoptosis (Chipuk et al., 2010) .
BCL-2 ovarian killer (BOK) shares sequence homology with BAX and BAK but has not been directly proven to be a proapoptotic effector (Echeverry et al., 2013) . Although BOK is frequently deleted in human cancers (Beroukhim et al., 2010) , genetic deletion of Bok in mice has not revealed an overt phenotype (Ke et al., 2012) . A recent study suggested that mouse embryonic fibroblasts (MEFs) lacking Bok are resistant to endoplasmic reticulum (ER)-stress-induced apoptosis and that ER stress in vivo reduces apoptosis in Bok-deficient livers (Carpio et al., 2015) . In contrast, another study (Ke et al., 2012) found that Bok-deficient thymocytes and MEFs show no defects in ER-stress-induced apoptosis and in some cases show increased sensitivity to ER stress.
ER stress leads to accumulation of unfolded proteins in the ER, which triggers the unfolded protein response (UPR) via three signaling pathways controlled by IRE1a, ATF6, or PERK (Walter and Ron, 2011) . Through its RNase activity, IRE1a activates the transcription factor XBP1 and regulates protein translation by degrading ER-localized mRNAs. The transcription factor ATF6 is activated through cleavage by Golgi-resident proteases S1P and S2P. The kinase PERK phosphorylates eIF2a, which in turn inhibits global protein translation while favoring the translation of UPR transcription factors such as ATF4 and CHOP, which coordinate UPR and ER-stress-induced apoptosis (Harding et al., 2000a (Harding et al., , 2000b .
These three pathways collaborate to resolve the accumulation of unfolded proteins by increasing the ER protein-folding capacity, transient inhibition of de novo protein synthesis, and degradation of unfolded ER proteins through ER-associated degradation (ERAD) (Smith et al., 2011) . During ERAD, unfolded (legend continued on next page)
proteins are retro-translocated from the ER lumen to the cytosol, where they are ubiquitylated and degraded by the proteasome. The failure to resolve ER stress can result in apoptosis via the mitochondrial pathway (Urra et al., 2013) . However, the specific role of ERAD in regulating the apoptotic response to ER stress remains unknown. Herein, we examined the regulation of BOK and its function in apoptosis. We found that BOK is an effector of MOMP that triggers membrane permeabilization and apoptosis in the absence of BAX and BAK. Strikingly, BOK did not require activation by BH3-only proteins and was not inhibited by antiapoptotic proteins BCL-2, BCL-xL, and MCL-1. BOK proapoptotic activity was controlled through ubiquitylation and ERAD by the E3 ubiquitin ligase AMFR/gp78, the AAA-ATPase VCP/p97, and the proteasome.
RESULTS

BOK Triggers Apoptosis in Response to Proteasome Inhibition
Because existing Bok-deficient models have yielded conflicting results (Carpio et al., 2015; Ke et al., 2012) , we generated a null allele of Bok in which exons 2-5 were removed, thereby deleting all coding sequences (Figures S1A-S1C). The expression pattern of BOK in wild-type (WT) tissues was similar to that reported previously (Ke et al., 2012) (Figure S1D ), and Bok À/À mice had no overt phenotype. MEFs derived from Bok À/À mice had no abnormalities in apoptosis induced by several agents, including the ER stressors tunicamycin (TN) and thapsigargin ( Figure S1E ). Importantly, we could not detect endogenous BOK expression in WT MEFs ( Figure S1F ). Thus, we studied BOK function under enforced expression. To follow BOK expression over time, we designed a doxycycline (dox)-inducible expression system wherein BOK is fused to a Venus fluorescent protein ( Figure S1G ). Dox induction of the Venus-BOK fusion in MEFs did not result in detectable Venus fluorescence unless cells were treated with proteasome inhibitors ( Figure 1A ). In contrast, other stressors could not stabilize the Venus-BOK fluorescence ( Figure 1A) . Further, together with NOXA and MCL-1, BOK was one of the most unstable BCL-2 family proteins ( Figure 1B) . Thus, like NOXA and MCL-1 (Ferná ndez et al., 2005; Nijhawan et al., 2003; Qin et al., 2005) , BOK might be regulated by proteasomal degradation. We developed a system for dox-inducible expression of BOK in WT MEFs, monitored as Venus 2A BOK ( Figure S1G ), in which Venus and BOK are produced in equimolar amounts as independent polypeptides. The Venus reporter and Bok mRNA were detected upon dox treatment ( Figures 1C and S1H ), but BOK protein was detected only when proteasome activity was inhibited ( Figure 1C ). Consistent with this finding, doxinduced BOK expression did not affect the rate or extent of apoptosis after treatment with several stressors but increased apoptosis in cells treated with the proteasome inhibitor MG132 ( Figures 1D and S1I) .
Next, we screened several tumor cell lines in which endogenous BOK was silenced by using small interfering RNA (siRNA) and examined clonogenic survival after transient treatment with MG132 ( Figure 1E ; downregulation efficiency is shown in Table S1 ). Several lines showed increased survival in response to proteasome inhibition when endogenous BOK was silenced ( Figure 1E , left). Of note, BOK was not detected in multiple myeloma cell lines U266 and H929 ( Figure S1J ), and siRNA silencing of BOK did not affect MG132-induced cell death in U266 cells ( Figure S1K ). MG132-induced apoptosis was significantly inhibited by BOK siRNA treatment in HCT116, T98G, and A172 cells ( Figure 1F ). Because the most striking response was observed in HCT116, it was used for further studies. Proteasome inhibition in HCT116 cells induced the stabilization of endogenous BOK (Figures S1L and S1M). Although the silencing of endogenous BOK in HCT116 cells inhibited MG132-induced cell death, it had no effect on other canonical apoptotic stimuli such as staurosporine, TNF plus cycloheximide, or the BH3-mimetic ABT-737 ( Figure 1G ). Therefore, BOK proapoptotic activity is likely regulated by proteasomal degradation and not by other proapoptotic stimuli.
BOK Triggers Apoptosis Independently of BAX and BAK
Most apoptotic stimuli cannot trigger MOMP or apoptosis in the absence of BAX and BAK (Lindsten et al., 2000; Wei et al., 2001 ). However, our finding that BOK is stabilized by proteasome inhibition, but not by other stressors that require BAX and/or BAK to engage apoptosis, prompted us to study whether BOK expression sensitizes Bax À/À Bak À/À (DKO) MEFs to apoptosis induced by proteasome inhibitors. Similar to WT MEFs, DKO MEFs did not express detectable levels of endogenous BOK unless BOK expression was enforced and the proteasome was inhibited (Figure S2A, bottom) . Treatment with different proteasome inhibitors induced cell death in DKO MEFs, but only under enforced BOK expression ( Figure 2A ). Other stressors (e.g., UV irradiation, actinomycin D, etoposide, staurosporine, TN, and thapsigargin) did not induce BOK stabilization or apoptosis in DKO MEFs under enforced BOK expression (Figures 2A and S2B ). In contrast, enforced expression of BAX or BAK sensitized DKO MEFs to apoptosis induction in response to all stressors tested (Figure S2B) . Of note, BOK-dependent cell death in DKO MEFs was caspase dependent ( Figure S2A ) and had characteristic features of apoptosis (membrane blebbing and Annexin V staining; Figure 2B ; Movies S1 and S2). HCT116 cells lacking BAX and BAK (DKO HCT-116), which are resistant to apoptosis induction by many stressors (Wang and Youle, 2012) , did not engage in apoptosis in response to TNF plus cycloheximide ( Figure 2C , left) but underwent BOK-dependent apoptosis upon proteasome inhibition by MG132 ( Figures  2C, S2C , and S2D). Strikingly, the kinetics of cell death in WT (F) Flow cytometry quantification of Annexin-V-stained HCT116, T98G, and A172 cells transfected with siRNA and treated with 10 mM MG132 for 30 hr (mean ± SD of three independent experiments). (G) IncuCyte quantification of SYTOX-Green-stained HCT116 cells treated with siRNA and MG132 (10 mM), ABT-737 (30 mM), staurosporine (2 mM), or a combination of TNF-a (50 ng/ml) and cycloheximide (CHX, 2 mg/ml). IncuCyte data are represented as mean of triplicate samples ± SD and representative of three independent experiments (see also Figure S1 ). and DKO HCT116 cells were similar after MG132 treatment, indicating that endogenous BOK is the main effector of apoptosis in this context ( Figure 2C, right) .
Proteasome inhibitors have shown promise in treating some malignancies in vivo (Nencioni et al., 2007) . Thus, we determined whether the proapoptotic capacity of BOK could mediate antitumor effects of proteasome inhibitors independently of BAX and BAK. DKO MEFs with or without dox-inducible BOK expression that were implanted into flanks of CD-1 nude mice generated tumors at the same rate in the absence of proteasome inhibition ( Figure 2D , left). DKO tumors (not expressing endogenous BOK even under proteasome inhibition; Figure S2A ) were resistant to treatment with the proteasome inhibitor bortezomib, but induction of BOK expression sensitized the tumors to bortezomib treatment and inhibited tumor growth ( Figure 2D, right) . Thus, the antitumor activity of proteasome inhibition in this system is due to BOK stabilization and induction of apoptosis. Figure S2 and Movies S1 and S2).
To further explore the conditions under which BOK can be stabilized to trigger apoptosis, we performed highthroughput screening of 4,282 small molecules with known biologic activity in DKO MEFs with enforced BOK expression to identify compounds that activate caspases in a BOK-dependent manner (Figures 2E, S2E, S2F, and S2G) . Most of the validated hits were known proteasome inhibitors ( Figure 2E ), but the screen also identified three natural compounds (anthotecol, obtusaquinone, and pomiferin) as new proteasome inhibitors (Figure S2G) . Further, two other agents, quinacrine and chlorothalonil, activated caspases in BOK-expressing cells. Although the latter compounds had no proteasome inhibitory activity ( Figure S2G ), they stabilized Venus-BOK expression ( Figure S2E ) and induced BOK-dependent cell death in DKO MEFs ( Figure S2F ) and were therefore investigated further.
BOK Is Regulated by Components of the ERAD Pathway
The stabilization of BOK expression by proteasome inhibitors might occur through BOK ubiquitylation by an E3-ubiquitin ligase and targeting for proteasomal degradation. Indeed, as reported for MCL-1 (Nijhawan et al., 2003) , MG132 treatment allowed the detection of BOK ubiquitylation ( Figure 3A ).
Tandem-affinity purification and mass spectrometry (MS) analysis revealed that four of six lysine residues in BOK are conjugated by ubiquitin (Ub) in MG132-stabilized BOK (Figure 3B) . Arginine substitution of all six lysines in BOK yielded a more stably expressed protein ( Figure 3C , top) that had increased killing activity upon transient expression (Figures 3C, bottom, and 3D) . Therefore, Ub-dependent regulation of BOK stability is an important determinant of its proapoptotic activity.
Next, we identified the E3-ligase responsible for BOK ubiquitylation by tandem affinity purification and proteomic screening. Because the C-terminal region of BOK associates with membranes (see below), which could result in potential artifactual interactions, we considered only interacting partners pulled down by both full-length BOK (BOK FL ) and a BOK version lacking the C terminus (BOK DC ). Both BOK pathway is critical for protein homeostasis by targeting unfolded ER proteins for proteasomal degradation (Smith et al., 2011) . In mammals, ubiquitylation of known ERAD substrates is primarily catalyzed by two ubiquitin ligase complexes inserted in the ER membrane and assembled around E3 ligases Hdr1 and gp78/AMFR (Fang et al., 2001; Kikkert et al., 2004) . Ubiquitylated substrates are then extracted from the ER by the VCP/p97 complex and processed for proteasomal degradation (Meyer et al., 2012) . Remarkably, our proteomic analysis revealed a BOK interaction network comprising three major ERAD compartments (Christianson et al., 2012; Fang et al., 2001) : the 26S proteasome; VCP and its cofactors Ufd1 and Npl4; and components of the gp78 E3 ubiquitin ligase complex, gp78, Erlin-1, Erlin-2, UBAC-2, and UBXD8 ( Figures 3E  and S3A ).
The association of BOK with its partners was further validated by immunoprecipitation and immunoblotting analysis ( Figure 3F ). The interaction between endogenous BOK and gp78 was observed after immunoprecipitation in untreated and MG132-treated HCT116 ( Figure S3B ). Mutation of the six lysines of BOK did not alter its interaction pattern ( Figure S3C) . Importantly, the C-terminal domain of BOK, which controls its subcellular localization (see below), was not sufficient for its interaction with gp78 ( Figure S3D ), suggesting that the cytosolic region of BOK is recognized by the ERAD pathway.
Live confocal microscopy analysis revealed that BOK and gp78 have a strong subcellular colocalization (Pearson's correlation coefficient 0.79; Figure 3G ). Gel filtration chromatography revealed that both gp78 and Erlin-2 co-eluted with BOK, further supporting that BOK associates with the gp78 E3 ubiquitin ligase complex ( Figure 3H ). Silencing of gp78 dramatically reduced BOK ubiquitylation ( Figure 3I ), which suggests that gp78 is a major catalyzer of BOK ubiquitylation.
During ERAD, gp78 catalyzes the ubiquitylation of unfolded ER proteins (Fang et al., 2001) , which are then extracted from the ER and presented to the proteasome by action of the AAAATPase VCP/p97 (Meyer et al., 2012) (Figure 4A ). Importantly, the silencing of gp78 or VCP stabilized BOK ( Figure S4A ) and induced cell death in DKO MEFs in the absence of proteasome inhibitors ( Figures 4B and S4B ). Inhibition of VCP by eeyarestatin I (ESI) (Wang et al., 2008 (Wang et al., , 2010 or NMS-873 (Magnaghi et al., 2013) stabilized BOK expression, but at a slower rate and to a lesser extent than did MG132 (Figures Figure S4 ).
4C and 4D). Consistent with this, these inhibitors induced caspase-dependent apoptosis in both WT and DKO MEFs under enforced BOK expression (Figure 4E) . NMS-873 also induced cell death in DKO HCT116 cells, which was largely prevented by silencing BOK (Figure 4F ; ESI induced non-apoptotic cell death in HCT116 and was therefore not further examined; data not shown). Therefore, conditions in which gp78 or VCP function is impaired promote BOK stabilization and lead to cell death.
Inhibition of PERK during ER Stress Induces ERAD Disruption and BOK-Induced Apoptosis
To test our observations that BOK is a sensor for ERAD dysfunction during ER stress, we determined the effect of compromised ERAD function on BOK expression and activity. During ER stress, accumulation of unfolded proteins in the ER activates the UPR through IRE1a, PERK, and ATF6 to upregulate ERAD components (Smith et al., 2011) . Therefore, we reasoned that a failure of these pathways during ER stress might impair the adaptive ERAD response and overwhelm the system. We found that Venus-BOK expression was not stabilized by inducing ER stress with TN alone (Figure 5A ), but its combination with a specific PERK inhibitor GSK2656157 (PERKi) (Atkins et al., 2013) stabilized BOK ( Figure 5A ). The stability of Venus-BOK was not affected by treatment with the IRE1a inhibitor 4m8C or the S1P protease (essential for ATF6 activation) inhibitor PF429242 alone or in combination with TN. Consistent with this, DKO HCT116 cells underwent cell death only when treated with TN plus PERKi and not TN in combination with inhibitors of components of the other UPR-associated signaling pathways ( Figure 5B ). Cell death induced by TN plus PERKi was caspase dependent and attenuated by silencing BOK (Figures 5B, S5A , and S5B). Therefore, PERK inhibition during TN-induced ER stress results in BOK stabilization and cell death induction in the absence of proteasome inhibition.
Bok mRNA was upregulated in TN-or MG132-treated HCT116 cells ( Figure S5C ), which suggests that during ER stress, BOKinduced cell death is regulated at not only the protein stability level but also the transcriptional level. However, increases in Bok mRNA levels were similar after treatment with TN alone or TN plus PERKi, but only the combination induced cell death in DKO HCT116 cells. Therefore, protein stabilization is a critical step for BOK-induced apoptosis in the absence of BAX and BAK.
Strikingly, cells treated with the combination of TN and PERKi, but not alone or in combination with other inhibitors, showed rapid loss of Erlin-1 and -2 ( Figure 5C ). This finding suggests that PERK activity is critical to sustain the integrity of the gp78 complex during ER stress. We determined whether this was due to transcriptional regulation of Erlin-1 and -2 by PERK signaling pathways. Although mRNAs encoding UPR proteins BiP, Edem, and ERdj4 were induced by ER stress (Rodriguez et al., 2012) , those for Erlin-1 and -2 were not affected by TN, alone or in combination with PERKi ( Figure S5D ). However, MG132 blocked the loss of Erlin-1 and -2 induced by the combination of TN and PERKi ( Figure 5D ), indicating that proteasomal activity mediates the degradation of these gp78 complex components under these conditions. To assess how the degradation of Erlin-1 and -2 affects gp78 function, we precipitated BOK from cells treated with MG132, ESI, or the combination of TN and PERKi ( Figure 5E ). BOK stabilization by MG132 or ESI led to co-precipitation of BOK with gp78, Erlin-1, and Erlin-2 (Figure 5E ). In contrast, BOK stabilization by TN and PERKi led to Figure S5 ).
degradation of Erlin-1 and -2 ( Figure 5E , left), and gp78 did not associate with BOK ( Figure 5E , right). This suggests that Erlin-1 and -2 are critical to recruit BOK to the gp78 complex. Accordingly, downregulation of Erlin-1 and -2 by siRNA silencing induced cell death in DKO MEFs upon BOK expression ( Figure S5E ). Our findings indicate that PERK signaling is critical to maintain gp78-dependent ERAD function during ER stress. Accumulation of unfolded proteins in the ER leads to PERK activation and eIF2a phosphorylation, which in turn inhibits global protein translation while favoring the translation of a small subset of proteins (e.g., ATF4 and CHOP) critical for the UPR (Harding et al., 2003; Lange et al., 2008) . We therefore tested whether collapse of the gp78 complex induced by PERK inhibition during ER stress could be prevented by downstream phosphorylation of eIF2a. We used the phosphatase inhibitor salubrinal, which inhibits eIF2a by preventing its dephosphorylation (Boyce et al., 2005) ( Figure S5F ). Alternatively, we subjected cells to amino acid deprivation, which promotes eIF2a phosphorylation, independently of PERK activation, via the kinase GCN2 (Dever et al., 1993) (Figure S5F ). Neither salubrinal nor amino acid starvation alone inhibited TN-induced ER stress (detected by monitoring PERK activation under those conditions; Figure S5G ), but both independently rescued Erlin-1 and -2 stability when used with TN plus PERKi ( Figure 5F ). Consistent with this pattern of Erlin-1 and -2 stabilization, salubrinal or amino acid starvation prevented the stabilization of BOK and apoptosis induced by TN plus PERKi ( Figures 5G and 5H ) but not by MG132 ( Figure S5H ). Together, these observations suggest that functionality of the gp78/Erlin E3 ubiquitin ligase complex is maintained during ER stress through a PERK/eIF2a signaling axis. Similar results were obtained when protein synthesis was inhibited by cycloheximide upon TN plus PERKi treatment ( Figures 5G, 5H , and S5A). Therefore, inhibition of protein translation by the PERK/ eIF2a signaling pathway during ER stress appears critical to maintain Erlin levels and prevent BOK expression.
We showed that regulation of BOK stability is a critical aspect of the cellular response to ER stress, and we mostly used proteasome inhibition to dissect this pathway. However, the identification of BOK inducers chlorothalonil and quinacrine from our high-throughput screen, which lack proteasome inhibitory activity ( Figures 2E, S2G , and 5I), suggested that they stabilize BOK upstream of the proteasome. Both compounds decreased the interaction of BOK and gp78, which suggests that they directly impair BOK recruitment to the gp78 E3 ubiquitin ligase complex ( Figure 5J ).
Taken together, our findings show that BOK can be independently stabilized by disrupting three distinct ERAD components: the proteasome, the VCP complex, and the gp78 E3 ubiquitin ligase complex. Thus, BOK might act as an apoptotic sensor that triggers cell death when the ERAD-proteasome degradation system is impaired.
BOK Is a Constitutively Active BCL-2 Family Effector that Is Not Regulated by BCL-2 Proteins
Upon activation by BH3-only proteins (e.g., BID or BIM) the BCL-2 pro-apoptotic effectors, BAX and BAK cause MOMP and the release of mitochondrial inter-membrane space proteins that function to engage caspase activation (Chipuk et al., 2010) . Owing to its sequence homology with BAX and BAK, BOK has been speculated to be a proapoptotic BCL-2 family effector protein, although experimental evidence supporting this function has been lacking (Echeverry et al., 2013) . We found that BOK stabilization by proteasome inhibition in DKO MEFs induced MOMP, causing release of the mitochondrial intermembrane space marker Omi-mCherry (Figures 6A and 6B ; Movies S3 and S4). Similarly, proteasome and ERAD inhibitors (MG132 and NMS-873, respectively), but not canonical apoptosis inducers (ABT-737, staurosporine, and TNF plus cycloheximide), triggered MOMP in DKO HCT116 cells ( Figure 6C ).
As previously reported (Echeverry et al., 2013) , we observed that BOK localizes to both the ER and mitochondria (Pearson's correlation coefficient 0.71 and 0.53, respectively) ( Figure S6A ). We studied whether this localization is important for degradation of BOK and its function in the mitochondria. BOK subcellular localization was controlled by its C-terminal domain, as shown by a Venus-C-terminal BOK fusion faithfully mimicking localization of the full-length protein ( Figure S6B ). We generated BOK variants in which the C terminus was ablated, resulting in cytosolic localization (BOK Cyto/DC ); replaced with the C terminus of Cb5 for strict ER localization (BOK ER ); or replaced with the C terminus of BCL-xL for mitochondrial localization (BOK Mito ). Localization of Venus-BOK targeted constructs was assessed by imaging ( Figure S6C ). In all cases, targeted BOK constructs were degraded ( Figure S6D ) and therefore inactive in causing apoptosis when expressed in DKO MEFs ( Figure 6D ). MG132 addition triggered apoptosis in WT and BOK Mito cells, but BOKCyto and BOK ER cells could not induce cell death in DKO MEFs ( Figure 6D ) despite being stabilized by MG132 ( Figure S6D ). These findings indicate that BOK must localize to the mitochondria to induce MOMP and apoptosis. The pore-forming activity of BAX and BAK can be shown in vitro by following the permeabilization of large unilamellar vesicles (LUVs) (Kuwana et al., 2002; Lovell et al., 2008) . BAX is a cytosolic protein, whereas BAK is a natural tail-anchored membrane protein. Therefore, in vitro LUV permeabilization requires tethering of BAK to the lipid bilayer, which is achieved using BAK DC -8xHIS and Nicoupled lipids (DGS-NTA(Ni)) in the LUVs (Oh et al., 2010) . Since BOK is also anchored in membranes via its C terminus ( Figures  S6B and S6C) , we examined the effects of BOK DC -8xHIS in Ni-NTA-LUVs. As expected, activation of full-length BAX or BAK DC -8xHIS with cleaved BID (n/c-BID) (Kuwana et al., 2002) resulted in rapid permeabilization of LUVs ( Figure 6E ). Importantly, this was not observed in the absence of BID or, in the case of BAK DC -8xHIS, in the absence of DGS-NTA(Ni) ( Figure 6E ). In all cases, LUV permeabilization correlated with membrane insertion of the protein, as shown by carbonate extraction ( Figure S6E) . BOK DC -8xHIS permeabilized LUVs ( Figure 6E ) and inserted into membranes ( Figure S6E ) in the presence of DGS-NTA(Ni). Thus, BOK is a pore-forming protein and therefore a bona fide effector of the BCL-2 family. Surprisingly, BOK activity did not seem to require BID ( Figure 6E ). Titration of BOK DC -8xHIS did not reveal any synergistic effect of BID on LUV permeabilization by BOK ( Figure S7A ), indicating that BID does not potentiate BOK pore-forming activity in vitro. It is possible, however, that another BH3-only protein activates BOK. Therefore, we tested six BH3 peptides for their ability to potentiate BOK activity. Only peptides of BID and BIM promoted LUV permeabilization by BAK, but no peptide affected LUV permeabilization by BOK (Figure 6F ). This suggests that unlike BAX and BAK, BOK does not require direct activation to engage its pore-forming activity. To further test this possibility, we exploited the ability of nonionic detergents to activate BAX and BAK (Hsu and Youle, 1997) . Treatment of BAK with n-octyl-D octylglucoside promoted its ability to permeabilize LUVs but did not affect LUV permeabilization by BOK ( Figure S7B ). These observations suggest that BOK, when stabilized, is constitutively active. To address this possibility, we examined the oligomeric state of BAX, BAK, and BOK in cells. Size exclusion chromatography ( Figure S7C ) and cross-linking analysis ( Figure S7D ) revealed that in untreated cells BAX and BAK behave as monomers and transition to oligomers upon challenge with etoposide, as described previously (Antonsson et al., 2000; Eskes et al., 2000) . In contrast, BOK was detectable only after MG132 treatment and revealed only a multimeric form. These results further support the idea that BOK, when stabilized, assumes an oligomeric state to function as a constitutively active BCL-2 effector protein that is regulated by rapid degradation in cells.
Antiapoptotic BCL-2 proteins prevent MOMP and apoptosis by sequestering the active forms of BAX and BAK and of the BH3-only proteins that activate them (Llambi et al., 2011) . Upon expression of BCL-2, BCL-xL, or MCL-1, BAX and BAK co-precipitated with the antiapoptotic proteins, with BCL-2 and MCL-1 showing preferences for BAX and BAK, respectively ( Figure 7A ), as previously described (Llambi et al., 2011; Willis et al., 2005; Zhai et al., 2008) . However, as reported previously (Echeverry et al., 2013) , we did not detect stabilized BOK in association with BCL-2 or BCL-xL and found that it only marginally bound to MCL-1 ( Figure 7A ). This interaction pattern was faithfully mimicked by chimeric tBID proteins, whose BH3 domain was exchanged with that of BAX, BAK, or BOK ( Figure S7E ). Since BOK was originally identified by an MCL-1 interaction in the yeast two-hybrid system , we measured the affinity of the BOK BH3 peptide for MCL-1 by surface plasmon resonance and found a K D of 3.0 mM compared with a K D of 108 nM for the BID BH3 binding ( Figure S7F) . Therefore, the absence of an interaction between BOK and antiapoptotic BCL-2 family members is probably due to the low affinity of its BH3 domain for these proteins.
Accordingly, although each of the antiapoptotic proteins prevented LUV permeabilization with BAK plus BID, LUV permeabilization by BOK was unaffected by BCL-2 or BCL-xL and, at best, only slightly delayed by the presence of MCL-1 ( Figure 7B ). Overexpression of BCL-2, BCL-xl, or MCL-1 in WT MEFs effectively blocked BAX-or BAK-dependent cell death in response to staurosporine but did not interfere with MG132-induced cell death in DKO MEFs that stably expressed BOK ( Figure 7C ). Similarly, HCT116 cells overexpressing the antiapoptotic proteins were resistant to various stressors ( Figure S7G ). However, cell death induced by MG132 or NMS-873 in HCT116 cells was completely resistant to the antiapoptotic effects of BCL-2, BCL-xL, or MCL-1 ( Figure 7D ), whereas silencing of endogenous BOK significantly inhibited apoptosis in all cell lines (Figure 7D) . Therefore, unlike BAX and BAK, BOK is an effector of MOMP and apoptosis that is not regulated by either proapoptotic BH3-only proteins or the major antiapoptotic BCL-2 proteins. Instead, BOK is likely regulated predominantly by the functions of gp78 and VCP to promote its rapid degradation ( Figure 7E ).
DISCUSSION
Although a role has been recently proposed for BOK in ER-stress-induced cell death (Carpio et al., 2015; Echeverry et al., 2013) , its function in the mitochondrial apoptotic pathway remains unclear. We show that like BAX and BAK, BOK is a bona fide effector of MOMP. Its pore-forming activity can trigger MOMP in the absence of BAX and BAK. Unlike BAX and BAK, however, BOK is constitutively active, independent of BH3-only proteins, and resistant to the antiapoptotic effect of BCL-2, BCL-xL, and MCL-1. Instead, BOK is controlled at the level of protein stability by the ERAD E3 ubiquitin ligase gp78 and its associated proteins Erlin-1, Erlin-2, and VCP, which target BOK for degradation by the proteasome to promote cell survival. When proteasome function, VCP, or gp78 activity is compromised, BOK is stabilized and induces MOMP to promote apoptosis.
Several mechanisms have been proposed to explain how the failure to resolve ER stress leads to terminal UPR, whereby the cell dies by apoptosis (Urra et al., 2013) . One mechanism involves PERK-dependent induction of ATF4 and CHOP, which promotes expression of the BH3-only protein BIM, leading to apoptosis in a BAX-or BAK-dependent manner (Puthalakath et al., 2007) . Paradoxically, and consistent with other reports (Back et al., 2009; Harding et al., 2000b) , we found that PERK inhibition did not result in resistance to ER-stress-induced apoptosis but rather to increased sensitivity to cell death induction (Figures 5 and S5) . Our study reveals a unique connection between PERK signaling and ERAD function. The inhibition of de novo protein synthesis by the PERK/eIF2a axis appears to be critical to sustain ERAD function under ER stress and increased unfolded protein burden. Failure of the PERK pathway in stressed cells leads to catastrophic failure of the gp78/Erlin complex (Figures 5 and S5) .
Another example of terminal UPR is accumulation of death receptor-5 at the ER, which then engages MOMP through caspase-8 activation and cleavage of the BH3-only protein BID (Lu et al., 2014) . Similarly to our study, this apoptotic pathway proceeds when a UPR signaling pathway fails (in this case IRE1a) during ER stress. This highlights how cell fate during ER stress is determined by apoptotic programs that are intricately ''wired'' into the UPR signaling pathways to trigger cell death.
Unlike conventional ERAD substrates that are degraded when misfolded, BOK seems to be a constitutive ERAD target that is continuously degraded in healthy cells. This notion is supported by the association of endogenous BOK with gp78 in HCT116 cells even in the absence of proteasome inhibition ( Figure S3B ). How the gp78 complex recruits BOK, however, is unclear. Erlin-1 and -2 appear to be critical for BOK degradation (Figures 5 and  S5 ) and could serve as key adaptors for ERAD targeting. This is reminiscent of inositol-1,4,5-triphosphate receptors that are processed by ERAD in an Erlin-1-and -2-dependent manner (Pearce et al., 2009) .
Some cells appeared to express BOK without succumbing to apoptosis, as seen in immunoblots of tissues from WT animals (confirmed in the same tissues from Bok À/À animals) (Figure S1D ). This suggests that BOK might be regulated by proteins other than BCL-2, BCL-xL, and MCL-1 or exist as a monomer until degraded by gp78 in such tissues. Alternatively, because BOK must localize to the mitochondria to trigger MOMP and apoptosis ( Figure 6D ), BOK sequestration at the ER might help keep its proapoptotic activity in check. Proteasome inhibitors have been used in cancer therapy (Nencioni et al., 2007) . Most studies on the mechanism of action of proteasome inhibitors in cancer cells have focused on the need for degradation in the NF-kB pathway (Nencioni et al., 2007) . Our work reveals that BOK represents an alternative route for MOMP and apoptosis that is unaffected by the loss of proapoptotic or the overexpression of antiapoptotic BCL-2 proteins. This raises the promising possibility of stabilizing BOK in cancer cells, in which the canonical mitochondrial pathway is often impaired. However, unlike BAX and BAK that are widely expressed across cell types and tissues, BOK has a restricted expression pattern. For example, BOK does not appear to be transcribed significantly in multiple myeloma (the Cancer Cell Line Encyclopedia database; http://www.broadinstitute.org/ ccle). Consistent with this, we did not find a key role for BOK in bortezomib-induced cell death in multiple myeloma cells (Figures S1J and S1K) . Nevertheless, our study suggests that cancer cells expressing high BOK mRNA levels may be particularly sensitive to treatment with proteasome inhibitors. Moreover, using specific ERAD inhibitors to trigger BOK-induced apoptosis in cancer cells can be a potential alternative therapy to proteasome inhibitors, which have pleiotropic side effects.
EXPERIMENTAL PROCEDURES
LUV Permeabilization Assay LUVs were prepared as described previously (Asciolla et al., 2012; Lovell et al., 2008) . Briefly, LUVs composed of 8% cardiolipin, 46% (or 41%) phosphatidylcholine, 25% phosphatidylethanolamine, 11% phosphatidylinositol, 10% phosphatidylserine, and when indicated, 5% DGS-NTA(Ni) (Avanti Polar Lipids) were loaded with the fluorophore ANTS (12.5 mM) and the quencher DPX (45 mM) (Molecular Probes). LUVs were incubated with the indicated concentration of recombinant proteins or BH3 peptides in 10 mM HEPES (pH 7.0), 200 mM KCl, and 5 mM MgCl 2 at 37 C, and permeabilization was assessed by measuring ANTS fluorescence over time with a spectrophotometer. The percentage of release was calculated between the baseline provided by the LUVsonly control and the 100% release obtained by LUVs solubilized in 1% CHAPS. Detergent-induced activation by n-octyl-b-D-glucoside (final concentration 0.015%) was performed as described previously (Asciolla et al., 2012 
Flow Cytometry
For Annexin V staining, cells were resuspended in Annexin V binding buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1mM MgCl 2 , and 1.8 mM CaCl 2 ) with Annexin V-APC (1/200; Caltag Laboratories). Annexin-V-positive cells were quantitated by flow cytometry, using FACScan and FACsCalibur systems (BD Biosciences) and FlowJo Collectors' Edition software (Tree Star). Flow cytometry data are represented as mean ± SD of three independent experiments, unless otherwise stated.
To monitor Omi-mCherry release, MEFs or HCT116 cells were incubated for 10 min on ice in PBS with 50 mg/ml or 333 mg/ml digitonin (Sigma-Aldrich), respectively, and washed twice in cold PBS. mCherry fluorescence was quantified by flow cytometry by using LSRII (BD Biosciences) and analyzed with FlowJo Collectors' Edition software.
IncuCyte Analysis
Venus-BOK stabilization and cell-death kinetics were monitored by the IncuCyte FLR or Zoom imaging system (Essen Bioscience). Dead cells were stained with 400 ng/ml propidium iodide (PI) or 25 nM SYTOX Green (Invitrogen) . In cases where percentages are indicated, total cell number was quantified using SYTO16 Green. SYTOX Green-, PI-, SYTO16 Green-, or Venuspositive cells were quantified by the IncuCyte image analysis software (Essen Bioscience). Data were expressed as positive events per well or as percentages of the ratio of PI to SYTO16 green counts (% cell death). IncuCyte data are representative of three independent experiments. Error bars represent the SD from the mean for triplicate samples.
Flank Tumor Model CD-1 nude mice were injected with 200 ml of a mixture containing 100 ml Matrigel Matrix (BD Biosciences) and 100 ml of PBS containing 4 3 10 
